National Centre for Pharmacoeconomics

National Centre for

NCPE Ireland

Reslizumab (Cinqaero®)

Cinqaero® is indicated as add-on therapy in adult patients with severe eosinophilic asthma inadequately controlled despite high-dose inhaled corticosteroids plus another medicinal product for maintenance treatment.

Rapid Review

Commenced Completed Outcome
23/01/2017 01/03/2017 Full Pharmacoeconomic Evaluation Recommended at the submitted price.

The HSE has approved reimbursement following confidential price negotiations; April 2019